Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy

References

• Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52(Pt 1):103–109.
   PubMed Web of Science ®Google Scholar
• Saito M, Suzuki H, Kono K, et al. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today. 2018;48(1):1–8.
   PubMed Web of Science ®Google Scholar
• Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 2017;22(1):81–88.
   PubMed Web of Science ®Google Scholar
• Goff SL, Dudley ME, Citrin DE, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol. 2016;34(20):2389–2397.
   PubMed Web of Science ®Google Scholar
• Stevanovic S, Helman SR, Wunderlich JR, et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res. 2019;25(5):1486–1493.
   PubMed Web of Science ®Google Scholar
• Ben-Avi R, Farhi R, Ben-Nun A, et al. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother. 2018;67(8):1221–1230.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.
   PubMed Web of Science ®Google Scholar
• Stevanovic S, Draper LM, Langhan MM, Campbell TE, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–1550.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332–342.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG. Tumor-infiltrating lymphocyte therapy: addressing prevailing questions. Cancer J. 2015;21(6):450–464.
   PubMed Web of Science ®Google Scholar
• Peng G, Wang HY, Peng W, et al. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27(2):334–348.
   PubMed Web of Science ®Google Scholar
• Mascaux C, Angelova M, Vasaturo A, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019;571(7766):570–575.
   PubMed Web of Science ®Google Scholar
• Song L, Ma S, Chen L, et al. Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer. Cancer Sci. 2019;110(7):2100–2109.
   PubMed Web of Science ®Google Scholar
• Bao Y, Guo L, Mo J. Characterization of gammadelta T cells in patients with non-small cell lung cancer. Oncol Lett. 2017;14(1):1133–1140.
   PubMed Web of Science ®Google Scholar
• Kansy BA, Concha-Benavente F, Srivastava RM, et al. PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res. 2017;77(22):6353–6364.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214–224.
   PubMed Web of Science ®Google Scholar
• Fernandez-Poma SM, Salas-Benito D, Lozano T, et al. Expansion of tumor-infiltrating CD8(+) T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy. Cancer Res. 2017;77(13):3672–3684.
   PubMed Web of Science ®Google Scholar
• Parkhurst M, Gros A, Pasetto A, et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin Cancer Res. 2017;23(10):2491–2505.
   PubMed Web of Science ®Google Scholar
• Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44–55.
   PubMed Web of Science ®Google Scholar
• Yossef R, Tran E, Deniger DC, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight. 2018;3(19):e122467.
   PubMed Web of Science ®Google Scholar
• Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002;168(10):4897–4906.
   PubMed Web of Science ®Google Scholar
• Sakellariou-Thompson D, Forget MA, Creasy C, et al. 4-1BB agonist focuses CD8(+) tumor-infiltrating T-cell growth into a distinct repertoire capable of tumor recognition in pancreatic cancer. Clin Cancer Res. 2017;23(23):7263–7275.
   PubMed Web of Science ®Google Scholar
• Segal NH, He AR, Doi T, et al. Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin Cancer Res. 2018;24(8):1816–1823.
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013;73(24):7189–7198.
   PubMed Web of Science ®Google Scholar
• Wu R, Forget MA, Chacon J, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012;18(2):160–175.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201–210.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12(10):671–684.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750–3759.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35(9):651–660.
   PubMed Web of Science ®Google Scholar
• Xia Y, Tian X, Wang J, et al. Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: a case report. Oncol Lett. 2018;16:6998–7007.
   PubMed Web of Science ®Google Scholar
• Zambricki E, Shigeoka A, Kishimoto H, et al. Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant. 2005;5(11):2623–2631.
   PubMed Web of Science ®Google Scholar
• Kaartinen T, Luostarinen A, Maliniemi P, et al. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy. 2017;19(9):1130.
   PubMed Web of Science ®Google Scholar
• Daley D, Zambirinis CP, Seifert L, et al. gammadelta T cells support pancreatic oncogenesis by restraining alphabeta T cell activation. Cell. 2016;166(6):1485–1499 e15.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim YA, Sim CK, et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. Oncotarget. 2017;8(69):113345–113359.
   PubMedGoogle Scholar
• Aktaş ON, Öztürk AB, Erman B, et al. Role of natural killer cells in lung cancer. J Cancer Res Clin Oncol. 2018;144(6):997–1003.,
   PubMed Web of Science ®Google Scholar
• Jewett A, Kos J, Kaur K, et al. Natural killer cells: diverse functions in tumor immunity and defects in pre-neoplastic and neoplastic stages of tumorigenesis. Mol Ther Oncol. 2020;16:41–52.
   PubMed Web of Science ®Google Scholar
• Valiathan R, Miguez MJ, Patel B, et al. Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study. PLoS One. 2014;9(5):e97698.
   PubMed Web of Science ®Google Scholar
• Moon EK. gammadeltaT cells in lung cancer malignant pleural effusion: friend? Foe? Am J Respir Cell Mol Biol. 2019;61(2):130–131.
   PubMed Web of Science ®Google Scholar
• Silva-Santos B, Serre K, Norell H. gammadelta T cells in cancer. Nat Rev Immunol. 2015;15(11):683–691.
   PubMed Web of Science ®Google Scholar
• Cheng M, Hu S. Lung-resident gammadelta T cells and their roles in lung diseases. Immunology. 2017;151(4):375–384.
   PubMed Web of Science ®Google Scholar
• Raverdeau M, Cunningham SP, Harmon C, et al. gammadelta T cells in cancer: a small population of lymphocytes with big implications. Clin Transl Immunol. 2019;8(10):e01080.
   PubMed Web of Science ®Google Scholar
• Rong L, Li K, Li R, et al. Analysis of tumor-infiltrating gamma delta T cells in rectal cancer. World J Gastroenterol. 2016;22(13):3573–3580.
   PubMed Web of Science ®Google Scholar
• Morrow ES, Roseweir A, Edwards J. The role of gamma delta T lymphocytes in breast cancer: a review. Trans Res J Lab Clin Med. 2019;203:88–96.
   Google Scholar
• Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–348.
   PubMed Web of Science ®Google Scholar
• Patil RS, Shah SU, Shrikhande SV, et al. IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer. 2016;139(4):869–881.
   PubMed Web of Science ®Google Scholar
• Ferrarini M, Heltai S, Chiesa G, et al. V delta 1+ gamma/delta T lymphocytes infiltrating human lung cancer express the CD8 alpha/alpha homodimer. Scand J Immunol. 1994;40(3):363–367.
   PubMed Web of Science ®Google Scholar
• Sakellariou-Thompson D, Forget MA, Hinchcliff E, et al. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother. 2019;68(11):1747–1757.
   PubMed Web of Science ®Google Scholar
• Caillon A, Mian MOR, Fraulob-Aquino JC, et al. gammadelta T cells mediate angiotensin II-induced hypertension and vascular injury. Circulation. 2017;135(22):2155–2162.
   PubMed Web of Science ®Google Scholar
• Nong J, Wang J, Gao X, et al. Circulating CD137(+) CD8(+) T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients. Scand J Immunol. 2019;89(6):e12765.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68.
   PubMed Web of Science ®Google Scholar
• Traitanon O, Gorbachev A, Bechtel JJ, et al. IL-15 induces alloreactive CD28(-) memory CD8 T cell proliferation and CTLA4-Ig resistant memory CD8 T cell activation. Am J Trans. 2014;14(6):1277–1289.
   PubMed Web of Science ®Google Scholar
• Pilipow K, Roberto A, Roederer M, et al. IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res. 2015;75(24):5187–5193.
   PubMed Web of Science ®Google Scholar
• Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181(10):6738–6746.
   PubMed Web of Science ®Google Scholar
• Bengsch B, Johnson AL, Kurachi M, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45(2):358–373.
   PubMed Web of Science ®Google Scholar
• Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128(4):887–896.
   PubMed Web of Science ®Google Scholar
• Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350–354.
   PubMed Web of Science ®Google Scholar
• Pilon-Thomas S, Kuhn L, Ellwanger S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012;35(8):615–620.
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111(11):5326–5333.
   PubMed Web of Science ®Google Scholar
• Butler MO, Friedlander P, Milstein MI, et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011;3(80):80ra34.
   PubMed Web of Science ®Google Scholar
• Yang S, Ji Y, Gattinoni L, et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother. 2013;62(4):727–736.
   PubMed Web of Science ®Google Scholar